Fig. 4
IgM+ B cells, low-density neutrophils, and monocytes prior to therapy associate with response of NSCLC patients to immune checkpoint inhibitors (ICI). IgM+ B cells prior to therapy associate with response to ICI (A, B). A Comparison of the percentages of IgM+ B cells at baseline between responder (R; n = 17) and non-responder (NonR; n = 33) NSCLC patients treated with anti-PD-1. B Kaplan–Meier analysis of IgM+ B cells at baseline with PFS. Low-density neutrophils (LDN) prior to therapy associate with response to ICI (LDNs identified as CD11b+CD66b+CD116+CD14−) (C). Progression-free survival (PFS; top) and overall survival (OS; bottom) stratified by the presence of baseline LDNs above the receiver operating characteristic (ROC) threshold (7.09%). Frequency of specific monocyte (Mo) subsets prior to therapy (identified through CyTOF analyses) are associated with responsiveness to anti-PD-1 (D, E). D Boxplots of statistically significant differences in conventional monocytes (cMo) CD33hi and non-conventional monocytes (nMo) CD9+ that differ between non-responder (NR) and R patients. E Geometric mean fluorescent intensity (gMFI) of CD33 expression on cMo validated by flow cytometry in PBMCs from patients with OS > vs. < 24 months. A, B modified from Xia, ref. [77]; copyright © 2022, Frontiers. C modified from Arasanz, ref. [78]; MDPI open access Creative Common CC BY License. D, E modified from Olingy, ref. [79]. copyright © 2022, Frontiers